Ketamine for Treatment Resistant Depression

Ketamine for Treatment Resistant Depression
Author: Sanjay J. Mathew,Carlos A. Zarate, Jr.
Publsiher: Springer
Total Pages: 155
Release: 2016-11-25
ISBN 10: 3319429256
ISBN 13: 9783319429250
Language: EN, FR, DE, ES & NL

Ketamine for Treatment Resistant Depression Book Review:

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.

Ketamine for Treatment Resistant Depression

Ketamine for Treatment Resistant Depression
Author: Gustavo H. Vazquez,Carlos A. Zarate,Elisa Brietzke
Publsiher: Academic Press
Total Pages: 168
Release: 2020-09-16
ISBN 10: 0128210346
ISBN 13: 9780128210345
Language: EN, FR, DE, ES & NL

Ketamine for Treatment Resistant Depression Book Review:

Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics. Provides efficacy research on ketamine as a treatment for depression Identifies best practices for clinical use, both long-term and acute Discusses the molecular mechanisms and neurobiology of action

Treatment resistant Mood Disorders

Treatment resistant Mood Disorders
Author: Andre Carvalho,Roger McIntyre
Publsiher: Oxford University Press, USA
Total Pages: 160
Release: 2014-05-01
ISBN 10: 0198707991
ISBN 13: 9780198707998
Language: EN, FR, DE, ES & NL

Treatment resistant Mood Disorders Book Review:

Treatment-resistant major depression and bipolar disorder are highly prevalent and disabling conditions associated with substantial morbidity and mortality. The assessment and management of refractory patients with mood disorders is a major clinical challenge for mental health providers. Part of the Oxford Psychiatry Library (OPL) series, this pocketbook provides a concise view of the current definitions, assessment and evidence-based management of treatment-resistant mood disorders and reviews novel therapeutic targets for mood disorders, which may enhance the therapeutic armamentarium of clinicians in the near future. The pocketbook serves as a useful guide for mental health practitioners, including psychiatrists, clinical psychologists, trainees, and interested primary care physicians.

Hello I Want to Die Please Fix Me

Hello I Want to Die Please Fix Me
Author: Anna Mehler Paperny
Publsiher: Random House Canada
Total Pages: 336
Release: 2019-08-06
ISBN 10: 0735272840
ISBN 13: 9780735272842
Language: EN, FR, DE, ES & NL

Hello I Want to Die Please Fix Me Book Review:

NATIONAL BESTSELLER SHORTLISTED FOR THE HILARY WESTON WRITERS' TRUST PRIZE FOR NONFICTION Award-winning journalist Anna Mehler Paperny's stunning memoir chronicles with courageous honesty and uncommon eloquence her experience of depression and her quest to explore what we know and don't know about this disease that afflicts almost a fifth of the population--providing an invaluable guide to a system struggling to find solutions. As fascinating as it is heartrending, as outrageously funny as it is serious, it is a must-read for anyone impacted by depression--and that's pretty much everybody. Depression is a havoc-wreaking illness that masquerades as personal failing and hijacks your life. After a major suicide attempt in her early twenties, Anna Mehler Paperny resolved to put her reporter's skills to use to get to know her enemy, setting off on a journey to understand her condition, the dizzying array of medical treatments on offer and a medical profession in search of answers. Charting the way depression wrecks so many, she maps competing schools of therapy, pharmacology, cutting-edge medicine, the pill-popping pitfalls of long-term treatment, the glaring unknowns and the institutional shortcomings that both patients and practitioners are up against. She interviews leading medical experts across Canada and the US, from psychiatrists to neurologists, brain-mapping pioneers to family practitioners, and others dabbling in strange hypotheses--and shares compassionate conversations with fellow sufferers. Hello I Want to Die Please Fix Me tracks Anna's quest for knowledge and her desire to get well. Impeccably reported, it is a profoundly compelling story about the human spirit and the myriad ways we treat (and fail to treat) the disease that accounts for more years swallowed up by disability than any other in the world.

Ketamine for Depression

Ketamine for Depression
Author: Dr. Stephen J. Hyde
Publsiher: Xlibris Corporation
Total Pages: 222
Release: 2015-09-04
ISBN 10: 1503509532
ISBN 13: 9781503509535
Language: EN, FR, DE, ES & NL

Ketamine for Depression Book Review:

Given the unacceptably high rates of suffering, disability and premature death experienced by people with treatment-resistant depression and the surprisingly low rates of problems arising from the use of ketamine to treat the disorder, this is a therapy that all patients and their doctors should be discussing. This book summarises the research that has been carried out into ketamine for the treatment of depression over the past 15 years and, most importantly, describes different ways of using ketamine that are both practical and cost–effective. Currently most ketamine therapy is given intravenously in specialised clinics at considerable expense, but the author has successfully treated patients with low-dose sublingual ketamine and his patients have been able to safely take this at home. Profits from the sales of this book will assist further research into the use of ketamine for the treatment of depression.

Rapid Acting Antidepressants

Rapid Acting Antidepressants
Author: Anonim
Publsiher: Academic Press
Total Pages: 402
Release: 2020-06-29
ISBN 10: 0128201908
ISBN 13: 9780128201909
Language: EN, FR, DE, ES & NL

Rapid Acting Antidepressants Book Review:

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field. Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series

Managing Treatment Resistant Depression

Managing Treatment Resistant Depression
Author: Joao Luciano de Quevedo,Patricio Riva-Posse,William V. Bobo
Publsiher: Elsevier
Total Pages: 820
Release: 2022-04-29
ISBN 10: 0128240679
ISBN 13: 9780128240670
Language: EN, FR, DE, ES & NL

Managing Treatment Resistant Depression Book Review:

Managing Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurobiological factors. In addition, staging methods for treatment resistance are fully covered in this book, including serotonin specific reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, other classes of antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors, augmentation strategies, and newer antidepressant treatments like ketamine and esketamine. In addition, evidence supporting the use of psychotherapies and neuromodulation strategies are also reviewed. Written by top experts in the field, this book is the first of its kind to review all methods of treatment for TRD. Defines Treatment-Resistant Depression and Staging Treatment Intensity Includes Treatment-Resistant Depression options for children, adolescents, geriatrics, during pregnancy, and during post-partum and menopause transitions Discusses the use of Ketamine and Esketamine for treatment-resistant depression

The Ketamine Papers

The Ketamine Papers
Author: Phil Wolfson,Glenn Hartelius
Publsiher: Unknown
Total Pages: 420
Release: 2016-11
ISBN 10: 9780998276502
ISBN 13: 0998276502
Language: EN, FR, DE, ES & NL

The Ketamine Papers Book Review:

The Ketamine Papers opens the door to a broad understanding of this medicine's growing use in psychiatry and its decades of history providing transformative personal experiences. Now gaining increasing recognition as a promising approach to the treatment of depression, posttraumatic stress disorder (PTSD), and other psychological conditions, ketamine therapies offer new hope for patients and clinicians alike. With multiple routes of administration and practices ranging from anesthesia to psychotherapy, ketamine medicine is a diverse and rapidly growing field. The Ketamine Papers clarifies the issues and is an inspiring introduction to this powerful tool for healing and transformation--from its early use in the 1960s to its emerging role in the treatment of depression, suicidality, and other conditions. This comprehensive volume is the ideal introduction for patients and clinicians alike, and for anyone interested in the therapeutic and transformative healing power of this revolutionary medicine.

Ketamine for Treatment Resistant Depression

Ketamine for Treatment Resistant Depression
Author: Gustavo H. Vazquez,Carlos A. Zarate,Elisa Brietzke
Publsiher: Academic Press
Total Pages: 150
Release: 2020-10-15
ISBN 10: 0128210338
ISBN 13: 9780128210338
Language: EN, FR, DE, ES & NL

Ketamine for Treatment Resistant Depression Book Review:

Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics. Provides efficacy research on ketamine as a treatment for depression Identifies best practices for clinical use, both long-term and acute Discusses the molecular mechanisms and neurobiology of action

Ketamine

Ketamine
Author: Kenji Hashimoto,Soichiro Ide,Kazutaka Ikeda
Publsiher: Springer Nature
Total Pages: 189
Release: 2020-03-05
ISBN 10: 9811529027
ISBN 13: 9789811529023
Language: EN, FR, DE, ES & NL

Ketamine Book Review:

This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which have remained elusive, describing and discussing important new research findings. Further, it explains insights gained from whole brain imaging in rodents and from behavioral pharmacology, and presents evidence regarding the role of gut microbiota, the NMDA receptor GluN2D subunit, and the lateral habenula in the actions of ketamine. These advances form the basis for the safer use of ketamine in patients with treatment-resistant depression and are expected to lead to the development of new antidepressants.

Manufacturing Depression

Manufacturing Depression
Author: Gary Greenberg
Publsiher: Simon and Schuster
Total Pages: 448
Release: 2010-02-02
ISBN 10: 9781416570080
ISBN 13: 141657008X
Language: EN, FR, DE, ES & NL

Manufacturing Depression Book Review:

Am I depressed or just unhappy? In the last two decades, antidepressants have become staples of our medicine cabinets—doctors now write 120 million prescriptions annually, at a cost of more than 10 billion dollars. At the same time, depression rates have skyrocketed; twenty percent of Americans are now expected to suffer from it during their lives. Doctors, and drug companies, claim that this convergence is a public health triumph: the recognition and treatment of an under-diagnosed illness. Gary Greenberg, a practicing therapist and longtime depressive, raises a more disturbing possibility: that the disease has been manufactured to suit (and sell) the cure. Greenberg draws on sources ranging from the Bible to current medical journals to show how the idea that unhappiness is an illness has been packaged and sold by brilliant scientists and shrewd marketing experts—and why it has been so successful. Part memoir, part intellectual history, part exposé—including a vivid chronicle of his participation in a clinical antidepressant trial—Manufacturing Depression is an incisive look at an epidemic that has changed the way we have come to think of ourselves.

Natural Medications for Psychiatric Disorders

Natural Medications for Psychiatric Disorders
Author: David Mischoulon,Jerrold F. Rosenbaum
Publsiher: Lippincott Williams & Wilkins
Total Pages: 386
Release: 2008
ISBN 10: 9780781767620
ISBN 13: 0781767628
Language: EN, FR, DE, ES & NL

Natural Medications for Psychiatric Disorders Book Review:

Updated for its Second Edition, this book is the only reference to focus exclusively on natural medications in psychiatry. Eminent psychiatrists from the Massachusetts General Hospital and other leading institutions examine current scientific and clinical data on the applications, effectiveness, and safety of natural psychotropics and acupuncture. Quick-reference tabular appendices list indications, contraindications, dosages, combinations, and drug-drug interactions for each remedy. This edition includes brand-new chapters on acupuncture, homeopathy, and therapies for substance dependence and weight management. The chapter on polypharmacy and side effect management addresses the growing issue of drug-drug interactions. New introductory chapters discuss complementary and alternative medicine in society and examine research limitations and quality assurance issues.

Cognition in Major Depressive Disorder

Cognition in Major Depressive Disorder
Author: Roger S. McIntyre,Danielle S. Cha,Joanna K. Soczynska
Publsiher: OUP Oxford
Total Pages: 128
Release: 2014-05-08
ISBN 10: 0191002623
ISBN 13: 9780191002625
Language: EN, FR, DE, ES & NL

Cognition in Major Depressive Disorder Book Review:

Part of the Oxford Psychiatry Library (OPL) series, Cognition in Major Depressive Disorder provides a succinct summary of cognitive deficits reported in patients with major depressive disorder (MDD) with a particular focus on aspects of measurement, underlying disease pathophysiology, implications for treatment and prevention. This book also provides readers an opportunity for clinical-based assessment of cognition and recommendations for how cognitive measurement and treatment is positioned in the management of individuals with mood disorders.

The Use Of Subcutaneous Ketamine For Treatment Resistant Depression

The Use Of Subcutaneous Ketamine For Treatment Resistant Depression
Author: Mariane Quieroti Rodrigues
Publsiher: Unknown
Total Pages: 135
Release: 2017
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1250394726
Language: EN, FR, DE, ES & NL

The Use Of Subcutaneous Ketamine For Treatment Resistant Depression Book Review:

Introduction: Major depressive disorder is highly common with up to 50% to 60% of the patients not achieving adequate response following antidepressant treatment. In this scenario, ketamine emerges as an important alternative to conventional treatments, with its action of being an antagonist of N-methyl- D-aspartate (NMDA) receptor, once its has a quick and effective action. Ketamine is most frequently administered intravenous. However, oral, sublingual, transmucosal, intranasal, subcutaneous (SC), and intramuscular routes of administration have also been examined.Aim: This study aims to investigate whether SC ketamine is effective in the treatment of unipolar major depression and if it has more effective and sustainable response than electroconvulsivetherapy (ECT).Methods: Participants will be comprised of patients with unipolar depression resistant to conventional treatment, men and women, aged u2265 18 across a range of ethnicities, recruited from General Hospital Servidor of State of Su00e3o Paulo, Brazil. Participants will be separeted in two groups. The first one will recieve a SC administration of ketamine in the dose of 0,5mg/kg weekly, for 6 weeks. The second will be submitted to ECT treatment, two sessions a week, for at least 8 sessions. The response of each treatment will be evaluated and compared by MADRS questionnaire.Results: We expect that SC ketamine has a good response in the treatment of major depression and that it has a similar response compared to ECT.Conclusion: SC ketamine, once it is a secure, quick and simple procedure, is a promising alternative to the available treatments.

Treatment resistant Depression Trd

Treatment resistant Depression Trd
Author: Deborah Diaz
Publsiher: Unknown
Total Pages: 100
Release: 2017-02-01
ISBN 10: 9781536108255
ISBN 13: 1536108251
Language: EN, FR, DE, ES & NL

Treatment resistant Depression Trd Book Review:

Major Depressive Disorder (MDD) is a common and debilitating neuropsychiatric disorder with high economic and societal impact. Approximately 30% of subjects with MDD achieve full remission after treatment with conventional antidepressants resulting in a relevant percentage of patients suffering from treatment resistant depression (TRD). Treating TRD is a difficult challenge for psychiatrists due to the complexity of this disabling condition. In fact, TRD is generally associated with a poorer outcome, higher suicidal risk, more severe psychosocial impairment and physical disability when compared to MDD. This book provides new research on treatment options, challenges and the future directions for individuals with TRD.

Ketamine Antidepressant Actions In Electroconvulsive Therapy Of Treatment Resistant Depression

Ketamine Antidepressant Actions In Electroconvulsive Therapy Of Treatment Resistant Depression
Author: Bruno Josu00e9 Prates
Publsiher: Unknown
Total Pages: 135
Release: 2017
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1250395833
Language: EN, FR, DE, ES & NL

Ketamine Antidepressant Actions In Electroconvulsive Therapy Of Treatment Resistant Depression Book Review:

Background and aims: Major depressive disorder affects approximately 5% of the population with nearly 1-third of patients failing to achieve remission, despite adequate pharmacological treatment [1]. Although electroconvulsive therapy (ECT) is the gold standard approach for treatment resistant depression (TRD), a considerable fraction of patients also show a delayed improvement or appear to be resistant to ECT. One of the most promising rapid-acting antidepressants is ketamine, a noncompetitive N-methyl-D-Aspartate receptor antagonist that can be used as an anesthetic during ECT to augment antidepressant efficacy [2].Data on ECTs using ketamine are both scarce and conflicting which lead the American Psychiatric Association to call for further studies [3]. We aim to clarify the potential synergism of ketamine and ECT for the treatment of TRD.Materials and methods: An experimental, non-randomized clinical trial with consecutive sampling of TRD patients with a HAM-D and PDAS scores u2265 23 was conducted. Patients that were initially assigned to 6 ECT sessions using thiopental anesthesia (ECT Std) but showed a very limited symptomatic relief were included in the study. Patients in Group 1 were then treated with further 6 ECT sessions using ketamine anesthesia (ECT Ket) whereas Group 2 maintained treatment with ECT Std (Fig. 1).Results: Clinical assessment showed no significant reduction in the mean HAM-D and PDAS scores for Group 1 but a significant reduction of the HAMD score of 38,8u00b12,4 to 13.4u00b110.55 (p

The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia

The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia
Author: American Psychiatric Association
Publsiher: American Psychiatric Pub
Total Pages: 218
Release: 2016
ISBN 10: 0890426775
ISBN 13: 9780890426777
Language: EN, FR, DE, ES & NL

The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia Book Review:

Dementia is associated with a sizeable public health burden that is growing rapidly as the population ages. In addition to cognitive impairments, individuals with dementia often come to clinical attention because of symptoms of a behavioral disturbance (e.g., irritability, agitation, aggression) or psychosis. The burden on caregivers is substantial and is increased when dementia is associated with behavioral and psychological symptoms, and particularly with agitation or aggression. Treatment of psychotic symptoms and agitation in individuals with dementia has often involved use of antipsychotic medications. In recent years, the risks associated with use of these agents in the older adult population have become apparent. There has been a growing need to develop guidelines for appropriate use of antipsychotic medications in dementia. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia seeks to fulfill this need to improve the care of patients with dementia who are exhibiting agitation or psychosis. The guideline focuses on the judicious use of antipsychotic medications when agitation or psychosis occurs in association with dementia. It is intended to apply to individuals with dementia in all settings of care as well as to care delivered by generalist and specialist clinicians. The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. Findings from an expert opinion survey have also been taken into consideration in making recommendations or suggestions. In addition to reviewing the available evidence on use of antipsychotics in treating agitation or psychosis in patients with dementia, the guideline provides guidance to clinicians on implementing these recommendations to enhance patient care.

ECDEU assessment manual for psychopharmacology

ECDEU assessment manual for psychopharmacology
Author: William Guy
Publsiher: Unknown
Total Pages: 612
Release: 1976
ISBN 10: 1928374650XXX
ISBN 13: UCR:31210000126621
Language: EN, FR, DE, ES & NL

ECDEU assessment manual for psychopharmacology Book Review:

Ketamine for Treatment Resistant Depression Or Post Traumatic Stress Disorder in Various Settings

Ketamine for Treatment Resistant Depression Or Post Traumatic Stress Disorder in Various Settings
Author: Joanne Kim
Publsiher: Unknown
Total Pages: 30
Release: 2017
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1000218458
Language: EN, FR, DE, ES & NL

Ketamine for Treatment Resistant Depression Or Post Traumatic Stress Disorder in Various Settings Book Review:

Complex Cases and Comorbidity in Eating Disorders

Complex Cases and Comorbidity in Eating Disorders
Author: Riccardo Dalle Grave,Massimiliano Sartirana,Simona Calugi
Publsiher: Springer Nature
Total Pages: 161
Release: 2021-03-26
ISBN 10: 3030693414
ISBN 13: 9783030693411
Language: EN, FR, DE, ES & NL

Complex Cases and Comorbidity in Eating Disorders Book Review:

In this book the authors share the strategies and procedures they use in their clinical daily practice to assess and treat complex cases of eating disorders. The strategic and pragmatic approach to the management of medical and psychiatric comorbidity coexisting with eating disorders, while relying on enhanced cognitive behavioral therapy (CBT-E) - an evidence-based treatment recommended for all eating disorder categories both in adults and adolescents-, can also be used by clinicians who adhere to different theoretical models. The book is divided into two main parts. Part I describes the eating disorder psychopathology and its consequences: an essential knowledge essential to understanding whether the patients have true comorbidity or spurious comorbidity. Then it gives an overview of CBT-E and how to implement it at different levels of care and in a multidisciplinary team. Part II illustrates the general strategies to address comorbidity in patients with eating disorders, and the specific strategies and procedures for managing the most common mental and general medical conditions coexisting with eating disorders. This volume is a valuable and useful tool for all clinicians - endocrinologists, nutritionists, dietitians, psychologists, psychiatrists - who deal with obesity and eating disorders.